Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias

  title={Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias},
  author={Susan E. Shoaf and Marcelo V{\'i}ctor Elizari and Zhao Wang and Kumara S Sekar and Liliana R. Grinfeld and N. Alejandro Barbagelata and Jorge Lerman and Steven L. Bramer and Jorge Trong{\'e} and Cesare Orlandi},
  journal={Journal of Cardiovascular Pharmacology and Therapeutics},
  pages={165 - 171}
Background: Tolvaptan, a nonpeptide selective vasopressin receptor (V2) antagonist, is in development for the treatment of congestive heart failure and hyponatremia. Tolvaptan is primarily metabolized via CYP3A4. This study was conducted to determine the extent of the pharmacokinetic interaction between tolvaptan and steady state amiodarone, an antiarrhythmic drug commonly prescribed for patients with congestive heart failure and a known inhibitor of other drugs metabolized by CYP3A4. Methods… 

Figures and Tables from this paper

Tolvaptan and its potential in the treatment of hyponatremia

  • ME DixonY. Lien
  • Medicine, Biology
    Therapeutics and clinical risk management
  • 2008
Tolvaptan is a breakthrough in the therapy of hyponatremia as it directly combats elevated AVP levels associated with the syndrome of inappropriate secretion of antidiuretic hormone, congestive heart failure, and cirrhosis of the liver.

Tolvaptan for the treatment of hyponatremia and congestive heart failure.

In patients with hyponatremia, tolvaptan appears to be more effective than fluid restriction at improving sodium levels without an increase in adverse events, and an international Phase III outcome study; Efficacy of Vasopressin antagonism in hEaRt failurE outcome Study with Tolvaptan (EVEREST), evaluating the long-term efficacy and safety of tolvaptic in patients hospitalized with worsening heart failure, is currently ongoing.

Tolvaptan for the treatment of heart failure: a review of the literature

Tolvaptan is unique in that it is virtually the only novel agent tested in patients hospitalized for acute heart failure syndrome (AHFS) to reach its primary end point for short-term efficacy without causing deleterious side effects.

Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study

It is suggested that in these patients 15 mg/day of tolvaptan should be sufficient, and increasing the dose or the frequency of dosing to overcome diuretic resistance should not be necessary, and consideration should be given to using a lower dose and/or prolonging the dosing interval.

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

Warfarin doses do not need to be altered when co‐administered with tolvaptan, and the protein binding of racemic warfarin and toLVaptan was not significantly altered by the presence of the other compound.

Update on tolvaptan for the treatment of hyponatremia

From a clinical perspective, tolvaptan has been shown to be efficacious in the treatment of hyponatremia, whether it is idiopathic or disease related, and it may have a more favorable benefit/risk profile than other treatment modalities.

Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome

Tolvaptan appeared to be well tolerated with a good safety profile, and it caused a significant reduction in pulmonary capillary wedge pressure compared with placebo, but has yet to demonstrate reversal of cardiac remodeling.

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients

The ability of tolvaptan to safely increase serum sodium concentration without activating the RAAS or compromising renal function and electrolyte balance makes it an attractive agent for treating hyponatremic HF patients.

Role of tolvaptan in acute decompensated heart failure

Tolvaptan, a vasopressin receptor antagonist, has been shown to improve diuresis and symptom relief without adversely affecting renal function, and may be a promising novel therapeutic agent in the growing population of patients with heart failure.

Tolvaptan, hyponatremia, and heart failure

This article reviews the accumulated experience with tolvaptan and all the major clinical trials that were conducted to study its safety and efficacy and concludes by summarizing clinicians’ views of its current application in clinical practice.



Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.

  • B. Singh
  • Medicine, Biology
    The American journal of cardiology
  • 1996

Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans.

The conservative dosing regimen used in this study is therapeutically effective, results in considerable interpatient variation in plasma drug and metabolite concentrations, slows the heart rate without significantly affecting other electrocardiographic parameters, and does not prevent keratopathy, cutaneous photosensitivity or hepatic dysfunction.

Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Preliminary studies indicate that amiodarone may have a beneficial effect on mortality and survival in certain groups of patients with ventricular arrhythmias, an action probably related to both its antiarrhythmic and antifibrillatory effects.

Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial.

Clinical efficacy of amiodarone as an antiarrhythmic agent.

The Influence of Atrial Fibrillation on Prognosis in Mild to Moderate Heart Failure The V‐HeFT Studies

Atrial fibrillation does not increase major morbidity or mortality in mild to moderate heart failure and hospitalization rate for heart failure was not increased in either study.